Dissolution Testing of new and special Dosage Forms - Updated FIP/AAPS Document
In 2003, the FIP Dissolution Working group published a position paper on dissolution/drug release testing for special and novel dosage forms that represented the scientific knowledge in the field at that time. This position paper from 2003 has given impetus in the scientific, technical, and regulatory community.
Due to the rapid evolution of new practices and techniques for dissolution/drug release testing, the FIP Special Interest Group on Dissolution/Drug Release decided to revise the previous paper.
In the recently presented Workshop Report the following dosage forms are discussed:
- Conventional solid drug products
- Oral suspensions
- Orally disintegrating tablets
- Chewable tablets
- Powders and granules
- Thin dissolvable films
- Chewing gums
- Dermal systems (patches)
- Topical systems (semisolid dosage forms)
- Suppositories
- Microparticulate formulations
- Implants
- Aerosols
Please find the extensive Report at "FIP/AAPS Joint Workshop Report: Dissolution/In Vitro Release Testing of Novel/Special Dosage Forms".
Author:
Dr. Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
18.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
18.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1
18.12.2025PharmaLab 2025: Brief Summary of AQCG Track - Save the Date for 2026!
18.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
17.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
17.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity



